Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.


Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 15 10 2020
revised: 19 01 2021
accepted: 30 01 2021
pubmed: 29 3 2021
medline: 14 5 2021
entrez: 28 3 2021
Statut: ppublish

Résumé

The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. This is a nationwide retrospective cohort study that was conducted in Mexico. Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection. The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RR To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.

Identifiants

pubmed: 33774512
pii: S0033-3506(21)00043-3
doi: 10.1016/j.puhe.2021.01.021
pmc: PMC7879028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113-115

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Références

Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Infect. 2021 Feb;82(2):282-327
pubmed: 32800801
Saf Health Work. 2020 Sep;11(3):262-265
pubmed: 32995051
BMC Infect Dis. 2020 Sep 16;20(1):674
pubmed: 32938419
J Infect. 2020 Oct;81(4):647-679
pubmed: 32417316

Auteurs

E Murillo-Zamora (E)

Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, Mexico; Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, Mexico. Electronic address: efren.murilloza@imss.gob.mx.

O Mendoza-Cano (O)

Facultad de Ingeniería Civil, Universidad de Colima, Km. 9 Carretera Colima-Coquimatlán, Coquimatlán, C.P. 28400, Colima, Mexico. Electronic address: oliver@ucol.mx.

I Delgado-Enciso (I)

Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, Mexico; Instituto Estatal de Cancerología de los Servicios de Salud del Estado de Colima, Av. Liceo de Varones 401, Col. La Esperanza, C.P 28085, Colima, Colima, Mexico. Electronic address: ivan_delgado_enciso@ucol.mx.

C M Hernandez-Suarez (CM)

Facultad de Ciencias, Universidad de Colima, Bernal Díaz del Castillo 340, Col. Villas San Sebastián, C.P. 28045, Mexico. Electronic address: carlosmh@mac.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH